Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238583 | 0.88 | LMNA (0.49) | MAPTKDM4EMAPK1HSD17B10ALOX15 | |
| SCHEMBL9427409 | 0.82 | MAPT (0.44) | MAPTGAAKDM4EMAPK1HSD17B10 | |
| SCHEMBL1569111 | 0.81 | MAPT (0.53) | MAPTGAAHSD17B10LMNAALDH1A1 | |
| SCHEMBL2235283 | 0.81 | GAA (0.46) | MAPTGAALMNAAKR1C3L3MBTL1 | |
| SCHEMBL15391580 | 0.80 | PPARG (0.46) | MAPTKDM4EMAPK1HSD17B10ALOX15 | |
| Nepafenac SCHEMBL93835 | 0.79 | ABCB11 (0.62) | MAPTGAALMNAABCB11PTGS1 | |
| Nepafenac SCHEMBL29377340 | 0.79 | ABCB11 (0.62) | MAPTGAALMNAABCB11PTGS1 | |
| SCHEMBL9427493 | 0.79 | MAPT (0.43) | MAPTGAAKDM4EMAPK1HSD17B10 | |
| SCHEMBL31299650 | 0.79 | CNR2 (0.46) | MAPTKDM4EMAPK1HSD17B10ALOX15 | |
| SCHEMBL27684778 | 0.79 | CNR2 (0.46) | MAPTKDM4EMAPK1HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590314-B1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2015-08-05 | — | — | EP | claimed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | claimed |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2011-08-11 | — | — | US | claimed |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2006-10-05 | — | — | US | claimed |
| EP-1590314-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2005-11-02 | — | — | EP | claimed |
| WO-2004069782-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2004-08-19 | — | — | WO | claimed |
| EP-1590314-B1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-10-21 | — | — | US | disclosed |
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-10-21 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
| EP-1590314-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069782-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | MAPT 4537/4885GAA 2973/4885KDM4E 4768/4885 |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | MAPT 4532/4885GAA 2998/4885KDM4E 4760/4885 |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | CXCR2, CXCR1, MMP8 | MAPT 4526/4885GAA 4554/4885KDM4E 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.